Fig. 1From: A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerMost common ganetespib-related grade 1/2 AEs in ≥20% of patients. None of the nine patients experienced DLTs. ALT alanine aminotransferase, AST aspartate transaminaseBack to article page